Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways. The three ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused ...

A diagnosis of advanced non-small-cell lung cancer (NSCLC) can bring a lot of questions. The FDA approved Jideytro (zidesamtinib) in 2026. It belongs to a group of medicines known as kinase inhibitors ...

Target high-unmet-need niches—post-immunotherapy resistance, rare biomarkers and early-stage disease—while tracking therapy uptake, pricing and market access.Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- ...

Phase II study shows promise in setting of third-generation EGFR TKI resistance ...

Racura Oncology (ASX:RAC) has been greenlit by a safety committee to increase to 100mg the dose of its novel RC220 drug for ...

ROS1-positive non-small cell lung cancer (NSCLC) is a rare lung cancer subtype occurring when part of the ROS1 gene fuses with another gene. Affecting around 1% to 2% of people with NSCLC, it tends to ...

A diagnosis of non-small cell lung cancer (NSCLC) can significantly affect emotional health, leading to mental health challenges such as depression, anxiety, and distress. Comprehensive mental health ...

Oct 6 (Reuters) - ArriVent BioPharma said on Tuesday its therapy to treat patients with a type of lung cancer did not meet the main goal in a late-stage trial. The company's shares were halted in ...

ROS1-positive non-small cell lung cancer (NSCLC) is a rare subtype of lung cancer that occurs when part of the ROS1 gene fuses with another gene. It affects about 1% to 2% of people with NSCLC and ...